Cargando…

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer

Synergism between anti-HER2 monoclonal antibody (trastuzumab) and paclitaxel has been shown in vitro and in vivo. In previous experiences, weekly administration of trastuzumab and paclitaxel has shown significant activity in metastatic breast cancer. In this phase II study, we evaluated the activity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gori, S, Colozza, M, Mosconi, A M, Franceschi, E, Basurto, C, Cherubini, R, Sidoni, A, Rulli, A, Bisacci, C, Angelis, V De, Crinò, L, Tonato, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395328/ https://www.ncbi.nlm.nih.gov/pubmed/14710203 http://dx.doi.org/10.1038/sj.bjc.6601485

Ejemplares similares

Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
por: Lee, Yu Rim, et al.
Publicado: (2011)

Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study
por: John, Matthias, et al.
Publicado: (2012)

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines
por: Berruti, A, et al.
Publicado: (2005)

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status
por: Irelli, Azzurra, et al.
Publicado: (2022)

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
por: Hurvitz, Sara A., et al.
Publicado: (2013)

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
por: Ishida, Takanori, et al.
Publicado: (2008)

Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
por: Joung, Eun Kyo, et al.
Publicado: (2021)

Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer
por: Batista, N, et al.
Publicado: (2004)

Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients
por: Kim, Jung Sun, et al.
Publicado: (2014)

Phase II Study of Pseudomonas aeruginosa-Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2–Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane
por: Lv, Fangfang, et al.
Publicado: (2015)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy
por: Ludovini, Vienna, et al.
Publicado: (2017)

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer
por: Helgason, H H, et al.
Publicado: (2006)

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
por: Swain, S M, et al.
Publicado: (2018)

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors
por: Nieto, Celia, et al.
Publicado: (2019)

Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023)

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study
por: Krop, Ian E., et al.
Publicado: (2022)

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
por: Palumbo, Raffaella, et al.
Publicado: (2015)

Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane
por: Ahn, Jin-Hee, et al.
Publicado: (2004)

Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer
por: Veronese, Pedro, et al.
Publicado: (2018)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
por: Chen, Wanjing, et al.
Publicado: (2021)

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients
por: Fabi, Alessandra, et al.
Publicado: (2015)

ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers
por: Abdel-Fatah, Tarek M. A., et al.
Publicado: (2019)

Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
por: Talbot, D C, et al.
Publicado: (2002)

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
por: Schreiber, Anna R., et al.
Publicado: (2021)

Erratum to: Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

A MicroRNA Expression Signature In Taxane-anthracycline-based Neoadjuvant Chemotherapy Response
por: Zheng, Yi, et al.
Publicado: (2015)

Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
por: Zhou, Li-Yan, et al.
Publicado: (2015)

Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
por: Lee, Jung Sun, et al.
Publicado: (2012)

Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity
por: Amaya, Celina, et al.
Publicado: (2022)

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
por: Park, Y H, et al.
Publicado: (2014)

Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline
por: Aomatsu, Naoki, et al.
Publicado: (2014)

Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy
por: Dai, Kun, et al.
Publicado: (2015)

Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment
por: Wang, Zhipeng, et al.
Publicado: (2018)

Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer
por: Vaid, Ashok K., et al.
Publicado: (2020)

A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy
por: Cheng, Pu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mv9vot43r8aqu2iq88p8nnuqj1